View in EDS PDF Full Text

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

Saved in:
Bibliographic Details
Title: A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Authors: Algazi AP; University of California-San Francisco, San Francisco, California, USA., Moon J; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Southwest Oncology Group Statistical Center, Seattle, Washington, USA., Lao CD; University of Michigan, Ann Arbor, Michigan, USA., Chmielowski B; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Kendra KL; The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Lewis KD; University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA., Gonzalez R; University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA., Kim K; California Pacific Medical Center Research Institute, San Francisco, California, USA., Godwin JE; Providence Cancer Institute, Portland, Oregon, USA., Curti BD; Providence Cancer Institute, Portland, Oregon, USA., Latkovic-Taber M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Lomeli SH; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Gufford BT; Labcorp Drug Development Inc., Madison, Wisconsin, USA., Scumpia PO; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Lo RS; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Othus M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Ribas A; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.
Source: Cancer [Cancer] 2024 May 15; Vol. 130 (10), pp. 1784-1796. Date of Electronic Publication: 2024 Jan 23.
Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38261444
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Algazi+AP%22">Algazi AP</searchLink>; University of California-San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Moon+J%22">Moon J</searchLink>; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Southwest Oncology Group Statistical Center, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Lao+CD%22">Lao CD</searchLink>; University of Michigan, Ann Arbor, Michigan, USA.<br /><searchLink fieldCode="AU" term="%22Chmielowski+B%22">Chmielowski B</searchLink>; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Kendra+KL%22">Kendra KL</searchLink>; The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Lewis+KD%22">Lewis KD</searchLink>; University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Gonzalez+R%22">Gonzalez R</searchLink>; University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Kim+K%22">Kim K</searchLink>; California Pacific Medical Center Research Institute, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Godwin+JE%22">Godwin JE</searchLink>; Providence Cancer Institute, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Curti+BD%22">Curti BD</searchLink>; Providence Cancer Institute, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Latkovic-Taber+M%22">Latkovic-Taber M</searchLink>; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Lomeli+SH%22">Lomeli SH</searchLink>; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Gufford+BT%22">Gufford BT</searchLink>; Labcorp Drug Development Inc., Madison, Wisconsin, USA.<br /><searchLink fieldCode="AU" term="%22Scumpia+PO%22">Scumpia PO</searchLink>; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Lo+RS%22">Lo RS</searchLink>; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Othus+M%22">Othus M</searchLink>; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Ribas+A%22">Ribas A</searchLink>; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2024 May 15; Vol. 130 (10), pp. 1784-1796. <i>Date of Electronic Publication: </i>2024 Jan 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38261444
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.35200
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1784
    Titles:
      – TitleFull: A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Algazi AP
      – PersonEntity:
          Name:
            NameFull: Moon J
      – PersonEntity:
          Name:
            NameFull: Lao CD
      – PersonEntity:
          Name:
            NameFull: Chmielowski B
      – PersonEntity:
          Name:
            NameFull: Kendra KL
      – PersonEntity:
          Name:
            NameFull: Lewis KD
      – PersonEntity:
          Name:
            NameFull: Gonzalez R
      – PersonEntity:
          Name:
            NameFull: Kim K
      – PersonEntity:
          Name:
            NameFull: Godwin JE
      – PersonEntity:
          Name:
            NameFull: Curti BD
      – PersonEntity:
          Name:
            NameFull: Latkovic-Taber M
      – PersonEntity:
          Name:
            NameFull: Lomeli SH
      – PersonEntity:
          Name:
            NameFull: Gufford BT
      – PersonEntity:
          Name:
            NameFull: Scumpia PO
      – PersonEntity:
          Name:
            NameFull: Lo RS
      – PersonEntity:
          Name:
            NameFull: Othus M
      – PersonEntity:
          Name:
            NameFull: Ribas A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 05
              Text: 2024 May 15
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 130
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1